The Long Term Impact of Initiating Pramipexole Versus Levodopa in Early Parkinson's Disease (CALM-PD Cohort Study) (CALM-PD Cohort)
Unblinded, Multicenter, Prospective Follow-up of Long-term Consequences of Initiating Patients With Parkinson's Disease on Either Pramipexole or Levodopa.
Sponsor: Boehringer Ingelheim
Terminated
Funding for the CALM-PD Cohort Study was terminated by sponsor.
Other terminated trials from Boehringer Ingelheim
Other Parkinson's Disease trials with similar outcome
Listed as NCT00804479, this observational or N/A phase trial focuses on Parkinson's Disease and remains terminated or withdrawn. Sponsored by Boehringer Ingelheim, it has been updated 6 times since 2002, reflecting limited change activity. This study adds to the evidence base for this therapeutic area through structured, versioned documentation.
Status Flow
Change History
6 versions recorded-
Sep 2024 — Present [monthly]
Terminated
-
Jul 2024 — Sep 2024 [monthly]
Terminated
-
Jan 2021 — Jul 2024 [monthly]
Terminated
-
Jun 2018 — Jan 2021 [monthly]
Terminated
-
Apr 2018 — Jun 2018 [monthly]
Terminated
Phase: NA → None
▶ Show 1 earlier version
-
Jan 2017 — Apr 2018 [monthly]
Terminated NA
First recorded
Jan 2002
Trial started
Per CT.gov start date — pre-dates our first snapshot
Eligibility Summary
No eligibility information available.
Contact Information
- Boehringer Ingelheim
- Pharmacia Corp. (Peapack, NJ)
- University of Rochester
For direct contact, visit the study record on ClinicalTrials.gov .